Article

Biomarkers for BCR-ABL1 as a Potential Therapeutic Option Among Adult Chronic Myeloid Leukaemia Treated With Tyrosine Kinase Inhibitors at Molecular Response in Multi-racial Malaysia: Hsa-mir-181a-5p for Decrement; hsa-mir-182-5p and hsa-mir-26a-5p for Increment.

2020-10-06

Abstract excerpt

<title>Abstract</title> <p>BackgroundTyrosine kinase inhibitors (TKIs) as first-line therapy for Chronic Myeloid Leukaemia (CML) show a high success rate. However, low number of patients with long-term treatment-free remission (TFR) is observed. Molecular relapse after imatinib discontinuation occurred at 50% at 24 months with 80% occurrence within the first 6 months. One of the reasons for relapse is untimely TK...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2bae3654-2fcc-50a7-bed1-9a6c095c3da0
DOI: 10.21203/rs.3.rs-78196/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Biomarkers for BCR-ABL1 as a Potential Therapeutic Option Among Adult Chronic Myeloid Leukaemia Treated With Tyrosine Kinase Inhibitors at Molecular Response in Multi-racial Malaysia: Hsa-mir-181a-5p for Decrement; hsa-mir-182-5p and hsa-mir-26a-5p for Increment.DOI 10.21203/rs.3.rs-78196/v1Read

MicroRNA signature refine response prediction in CMLSemantic proximity Read

Contribution of BCR-ABL molecular variants and leukemic stem cells in response and resistance to tyrosine kinase inhibitors: a reviewSemantic proximity Read

Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical RelevanceSemantic proximity Read

Treatment and molecular monitoring update in chronic myeloid leukemia management.Semantic proximity Read

Mutation analysis of BCR-ABL1 kinase domain in chronic myeloid leukemia patients with tyrosine kinase inhibitors resistance: a Malaysian cohort study.Semantic proximity Read

Molecular monitoring in CML: how deep? How often? How should it influence therapy?Semantic proximity Read

Shorter halving time of BCR‐ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic‐phase chronic myeloid leukemia treated with dasatinib: Results of the D‐first study of K anto CML study groupSemantic proximity Read

A Review on the Therapeutic Role of TKIs in Case of CML in Combination With Epigenetic DrugsSemantic proximity Read

MUTATIONAL STATUS AND TREATMENT EFFICACY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA.Semantic proximity Read

Best Practices in Chronic Myeloid Leukemia Monitoring and Management.Semantic proximity Read

Molecular monitoring of chronic myeloid leukemia: present and future.Semantic proximity Read

Clinical Significance of the S348l Mutation in BCR-ABL as a Dominant Variant in Indonesian CML Patients Under Tyrosine Kinase Inhibitor Therapy: A Cohort Study.Semantic proximity Read